methotrexate has been researched along with Dyslipidemia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Farley Prater, EA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Wong, EB; Wu, JJ | 1 |
| Català, A; Puig, L; Roé, E; Vilarrasa, E; Yélamos, O | 1 |
| Bruckert, E; Hansel, B | 1 |
| Ferrazzi, A; Girolomoni, G; Gisondi, P | 1 |
| Barthelemy, H; Beauchet, A; Begon, E; Boyé, T; Bravard, P; Chaby, G; Descamps, V; Estève, E; Girard, C; Maccari, F; Mahé, E; Maillard, H; Quiles-Tsimaratos, N; Reguiai, Z; Schmutz, JL; Sigal, ML | 1 |
2 review(s) available for methotrexate and Dyslipidemia
| Article | Year |
|---|---|
[Lipid profile and cardiovascular risk in patients with rheumatoid arthritis: Effect of the disease and of drug therapy].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Atherosclerosis; Cardiovascular Diseases; Chronic Disease; Dyslipidemias; Female; Glucocorticoids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Lipid Metabolism; Lipids; Lipoproteins; Male; Methotrexate; Risk Factors | 2010 |
Metabolic comorbidities and psoriasis.
Topics: Arthritis, Psoriatic; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Liver; Humans; Hypertriglyceridemia; Immunosuppressive Agents; Insulin Resistance; Metabolic Syndrome; Methotrexate; Non-alcoholic Fatty Liver Disease; Obesity; Psoriasis; Risk Factors | 2010 |
3 other study(ies) available for methotrexate and Dyslipidemia
| Article | Year |
|---|---|
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
Topics: Adolescent; Adrenal Cortex Hormones; Anthralin; Biological Products; Calcineurin Inhibitors; Cardiovascular Diseases; Child; Child, Preschool; Coal Tar; Comorbidity; Cyclosporine; Dermatologic Agents; Dyslipidemias; Evidence-Based Medicine; Humans; Infant; Infant, Newborn; Inflammatory Bowel Diseases; Insulin Resistance; Mental Health; Metabolic Syndrome; Methotrexate; Nicotinic Acids; Obesity; Photochemotherapy; Psoriasis; Retinoids | 2020 |
Acute severe methotrexate toxicity in patients with psoriasis: a case series and discussion.
Topics: Acute Disease; Aged, 80 and over; Atrial Fibrillation; Deglutition Disorders; Drug Eruptions; Dyslipidemias; Fever; Humans; Hypertension; Immunosuppressive Agents; Male; Medication Errors; Methotrexate; Middle Aged; Oral Ulcer; Pancytopenia; Psoriasis; Renal Insufficiency, Chronic; Shock, Septic | 2014 |
Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Diet; Dyslipidemias; Female; Humans; Hypertension; Immunosuppressive Agents; Infliximab; Male; Methotrexate; Middle Aged; Obesity; Psoriasis; Retrospective Studies; Risk Factors; Severity of Illness Index; Sex Factors; Smoking; Weight Gain | 2014 |